DR. JOAN M FALLON, DC
Neurology at Central Park Ave, Yonkers, NY
License number
New York 003594
Category
Chiropractic
Type
Neurology
Address
Address
1234 Central Park Ave SUITE 1B, Yonkers, NY 10704
Phone
(914) 779-9300
(914) 779-1148 (Fax)
(914) 779-1148 (Fax)
Personal information
See more information about JOAN M FALLON at radaris.comName
Address
Phone
54 Schriever Ln, New City, NY 10956
3547 33Rd St APT 2D, Long Island City, NY 11106
411 W 24Th St APT 5A, New York, NY 10011
46 Bircher Ave, Poughkeepsie, NY 12601
46 Steven Pl, Smithtown, NY 11787
Professional information
Joan M Fallon, Yonkers NY
Specialties:
Chiropractor
Address:
1234 Central Park Ave, Yonkers, NY 10704
Methods And Compositions For The Treatment Of Symptoms Of Neurological And Mental Health Disorders
US Patent:
2011018, Jul 28, 2011
Filed:
Jul 1, 2009
Appl. No.:
13/002136
Inventors:
Joan M. Fallon - Bronxville NY, US
International Classification:
A61K 38/54, A61K 38/43, A61K 38/48, A61K 38/47, A61K 38/46, C12Q 1/37, A61K 49/00, A61P 25/00, A61P 25/28, A61P 25/18
US Classification:
424 92, 424 941, 424 9463, 424 9461, 424 946, 424 9465, 424 9464, 424 942, 435 23, 424 91
Abstract:
A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
Methods And Compositions For The Prevention And Treatment Of Influenza
US Patent:
2012025, Oct 11, 2012
Filed:
Oct 21, 2010
Appl. No.:
13/502989
Inventors:
Joan M. Fallon - Bronxville NY, US
Matthew F. Heil - Sherman CT, US
James J. Fallon - Armonk NY, US
James Szigethy - Montgomery NY, US
Matthew F. Heil - Sherman CT, US
James J. Fallon - Armonk NY, US
James Szigethy - Montgomery NY, US
Assignee:
CUREMARK LLC - Rye NY
International Classification:
A61K 38/54, A01P 1/00, A01N 63/02, A61K 39/145, A61P 31/16, A61K 9/00
US Classification:
424400, 424 942, 4242091
Abstract:
This disclosure relates to the prevention and treatment of Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes. The disclosure further relates to the use of an individual's fecal chymotrypsin level as an indicator e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.
Methods For Diagnosing Pervasive Development Disorders, Dysautonomia And Other Neurological Conditions
US Patent:
8030002, Oct 4, 2011
Filed:
Nov 16, 2001
Appl. No.:
09/990909
Inventors:
Joan M. Fallon - Yonkers NY, US
Assignee:
Curemark LLC - Rye NY
International Classification:
G01N 33/53, G01N 33/554, G01N 33/573, C12Q 1/02
US Classification:
435 71, 435 72, 435 732, 435 74, 435 29
Abstract:
Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the individual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, , Adenovirus, Rotavirus or.
Methods Of Treating Pervasive Development Disorders
US Patent:
2002009, Jul 11, 2002
Filed:
Dec 31, 2001
Appl. No.:
10/041073
Inventors:
Joan Fallon - Yonkers NY, US
International Classification:
G01N033/53, C12Q001/37
US Classification:
435/007100, 435/023000
Abstract:
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.
Use Of Lactulose In The Treatment Of Autism
US Patent:
2008016, Jul 3, 2008
Filed:
Mar 17, 2008
Appl. No.:
12/049613
Inventors:
Joan M. Fallon - Yonkers NY, US
Richard Feltenstein - New Rochelle NY, US
Richard Feltenstein - New Rochelle NY, US
International Classification:
A61K 31/7016, A61P 43/00
US Classification:
514 53
Abstract:
A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
Method For Treating Pervasive Development Disorders
US Patent:
2012020, Aug 16, 2012
Filed:
Apr 16, 2012
Appl. No.:
13/448061
Inventors:
JOAN M. FALLON - Bronxville NY, US
Assignee:
CUREMARK, LLC - Rye NY
International Classification:
A61K 38/54, A61P 1/18
US Classification:
424 9421
Abstract:
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
Method For The Treatment Of The Symptoms Of Drug And Alcohol Addiction
US Patent:
8084025, Dec 27, 2011
Filed:
Apr 20, 2009
Appl. No.:
12/426794
Inventors:
Joan M. Fallon - Bronxville NY, US
Assignee:
Curemark LLC - Rye NY
International Classification:
A61K 38/46
US Classification:
424 946, 424 9463, 424 9461, 435195, 435198, 435201, 435202, 435212, 435213, 435219
Abstract:
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
Methods Of Treating And Diagnosing Parkinsons Disease And Related Dysautonomic Disorders
US Patent:
2008015, Jun 26, 2008
Filed:
Mar 11, 2008
Appl. No.:
12/046252
Inventors:
Joan M. Fallon - Yonkers NY, US
International Classification:
A61K 38/54, A61P 1/14
US Classification:
424 942
Abstract:
A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.
Method For Treating Pervasive Development Disorders
US Patent:
8613918, Dec 24, 2013
Filed:
May 25, 2012
Appl. No.:
13/481087
Inventors:
Joan M. Fallon - Bronxville NY, US
Assignee:
Curemark LLC - Rye NY
International Classification:
A61K 38/54, A61K 35/39, G01N 21/47, G01J 3/42, C12Q 1/37
US Classification:
424 9421, 424 942, 356319, 435 74, 435 23, 435 24, 435803, 514 55, 514 128, 514 175
Abstract:
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.